OnKure Therapeutics (OKUR) Q1 2025 earnings summary

Executive summary

• Completed a reverse merger with Reneo Pharmaceuticals, resulting in recapitalization and $65 million in new equity financing; now trades on Nasdaq under OKUR.

• Advanced PIKture-01 trial with OKI-219, completing Part A dose escalation and progressing Part B combination arm; mature data expected in H2 2025.

• Announced plans to introduce a pan-mutant selective PI3Ka inhibitor candidate in Q2 2025.

• No product revenue to date; operations funded by equity and convertible debt; cash runway expected to last at least 12 months from March 2025, with some projections into Q4 2026.

Financial highlights

• Net loss of $15.9 million for Q1 2025, or $1.19 per share, compared to $9.5 million, or $30.37 per share, in Q1 2024.

• Research and development expenses increased to $13.0 million in Q1 2025, mainly due to personnel and clinical trial costs.

• General and administrative expenses rose to $4.0 million in Q1 2025, reflecting higher personnel and professional fees.

• Interest income increased to $1.1 million in Q1 2025, reflecting higher cash balances post-merger.

• Cash and cash equivalents were $96.7 million as of March 31, 2025.

Outlook and guidance

• Expects to present mature single-agent and initial combination data from PIKture-01 in H2 2025.

• Plans to announce a pan-mutant PI3Ka development candidate in Q2 2025.

• R&D and G&A expenses expected to increase in 2025 as programs advance and public company costs are incurred.

• Cash resources projected to fund operations for at least the next 12 months, with some guidance extending into Q4 2026; additional capital will be needed for long-term development.